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Abstract
Background: Abatacept (ABA) is a fusion receptor protein containing the CTLA-4 domain that prevents the
activation of naïve T cells by binding the CD80 and CD86 molecules expressed on the surface of dendritic cells,
indicated for the treatment of moderate to severe rheumatoid arthritis (RA). There is still little evidence concerning
the safety of ABA in RA patients with positive serology for hepatitis virus B (HBV) infection.
Case Presentation: We report the case of a HBV infection reactivation in an ABA-treated male RA patient. The
patient (caucasian race, 66-year-old) was diagnosed with RA in Novembre 2010 and in December 2010 he started a
treatment with prednisone plus subcutaneous methotrexate. In October 2011, an anti-TNF agent (golimumab) was
added but soon discontinued due to an adverse event. At baseline, screening for HBV markers showed a positivity
for HBcAb and HBeAb IgG, being HBsAg, HBsAb, HBcAb IgM, HBeAg and HBV DNA negative. Serum amino-transferase
(AST and ALT) levels were within the normal range. In January 2012 he was swapped to intravenous treatment with ABA
750 mg/month, that allowed the achievement of a good clinical response and the permanent discontinuation
of corticosteroids. In November 2013, laboratory reports showed that he was positive for HBcAb but negative
for the remaining HBV markers, and had a slightly increased AST level and, in December 2013, he became HBV
DNA positive (326 IU/mL). In January 2014, his HBV DNA levels had further increased and ABA was stopped
while maintaining MTX. He started lamivudine 100 mg/day in January 2014. After 1 month of lamivudine, his
HBV DNA levels became undetectable (<10 IU/mL) and liver function was normal although RA had been reactivated
(DAS28 5.53). Treatment with ABA was therefore resumed with the achievement of a good response after
6 months. The patient is currently being treated with lamivudine 100 mg/day, i.v. ABA 750 mg/month, and
MTX 15 mg/week, with a good response (DAS28 2.27 in October 2015), and constantly monitored without any
further evidence of HBV infection reactivation.
Conclusions: Although there are still few reports in literature, we suggest caution in HBV- occult carriers RA
patients undergoing a treatment with abatacept.
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Background
The treatment of rheumatoid arthritis (RA) includes many
biologic drugs blocking different steps of the inflammatory
cascade. Abatacept (ABA) is a fusion receptor protein
containing the CTLA-4 domain that prevents the activa-
tion of naïve T-cells by binding CD80 and CD86 expressed
on the surface of dendritic cells [1]. Abatacept, with or
without methotrexate (MTX), is approved for treating
moderate to severe RA in patients refractory to previous
disease modifying anti-rheumatic drugs (DMARDs) and
anti- TNF drugs.
Evidences show the safety of ABA in RA patients with
positive serology for hepatitis virus (HBV) infection [2],
and there are few reports of HBV reactivation. We ob-
served a case of HBV infection reactivation in a Cauca-
sian male patient affected by RA treated with ABA.
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Case presentation
The patient, 66 years old, was diagnosed with RA in
November 2010 according to the new European League
Against Rheumatisms (EULAR)/American College of
Rheumatology (ACR) 2010 criteria [3]. At baseline clin-
ical examination showed 23 swollen joints and 26 tender
joints, increased values of Erythrocyte Sedimentation
Rate (ESR), C-Reactive Protein (CRP) and of Rheuma-
toid Factor (RF) (15 mg/L) and anti-citrullinated pep-
tides antibodies (ACPA). Complete blood count, serum
amino-transferases and creatinine were within the range
of normality. X-rays of both hands and feet showed juxta
articular osteoporosis but no bone erosions.
In December 2010 he started a treatment with prednis-
one 5 mg/day plus subcutaneous MTX 10 mg/week,
which was increased up to 15 mg/week in February 2011.
Due to persistent disease activity (DAS28 = 4.16), in Octo-
ber 2011 the patient was considered candidate to a bio-
logic agent according to the Italian guidelines and
therefore a screening for opportunistic infections was re-
quired [4]. Tuberculosis screening assessed by interferon-
gamma release assay (IGRA) proved negative. Thorax X-
rays showed no pleural or pulmonary lesion. Hepatitis
screening showed a positivity for HBcAb IgG and HBeAb
IgG, while HBsAg, HBsAb, HBcAb IgM, HBeAg and
HCV-Ab were negative. HBV DNA was negative (<20 IU/
mL), AST and ALT value were within the normal range
(20 and 27 IU/L respectively). In November 2011 a ther-
apy with golimumab 50 mg every month was started, but
it was permanently discontinued after three weeks due to
adverse effects (cough and tachycardia). In January 2012
the patient was swapped to a treatment with abatacept
(ABA) e.v. 750 mg monthly. At baseline DAS28 was 4.85;
CRP value was 19 mg/L (normal values < 1 mg/L), ESR
21 mm (normal values < 27 mm), AST 18 IU/L (normal
values < 40 IU/L) and ALT 30 IU/L (normal values < 40
IU/L).
HBV DNA, AST and ALT were evaluated every three
months, and remained within the normal range. The re-
sponse to ABA therapy was good with DAS28 achieving
the score of 2.31 after 3 months. The patient maintained a
clinical remission at the follow-up visits despite the taper-
ing and the definitive discontinuation of corticosteroids.
However, in November 2013 laboratory reports showed
a positivity in HBcAb with a negativity in the remaining
HBV serologic markers (HBsAg, HBcAb, HBeAg, HBeAb,
HCV-Ab) and a mild increase in the value of AST (41 IU/
L). Furthermore, in December 2013 HBV DNA turned
positive with a level of 326 IU/mL (normal range <20 IU/
mL). In January 2014, a subsequent control of HBV-DNA
revealed a further increase up to 1416 IU/mL. ABA was
then stopped maintaining MTX, and the patient referred
to a hepatologist. A liver examination by means of abdom-
inal ultrasound was done, resulting into normal findings.
However, since January 2014 a treatment with lamivudine
100 mg/day was started.
After 1 month of lamivudine, HBV DNA became un-
detectable (<10 IU/mL) and liver functionality was normal
(AST 29 IU/L, ALT 38 IU/L); on the contrary CRP values
were greatly increased (42.4 mg/L) and RA reactivated
(DAS28 = 5.53); therefore the treatment with ABA was
reintroduced. The patient experimented a rapid benefit on
the rheumatic symptoms reaching a good EULAR re-
sponse after 3 months. In April 2014 liver functionality
was good (AST 29 IU/L, ALT 31 IU/L), HBV-DNA was
<10 IU/mL and an assessment through Fibroscan showed
an index of stiffness of 3.9 kPA.
The patient is currently treated with lamivudine
100 mg/day, i.v. abatacept 750 mg every month and
MTX 15 mg/week with a good response (DAS28 = 2.27
in October 2015). Figure 1 illustrates the time-course of
DAS28, AST, ALT and HBV DNA levels.
Conclusions
The association between ABA and HBV infection is
still unclear. Germanidis et al. [5] reported the case of
a elderly RA woman who developed an active HBV
hepatitis after 1 year of treatment with ABA. The pa-
tient was concomitantly treated with prednisone
10 mg/day and leflunomide 20 mg/day, perhaps
favouring the viral reactivation. Our patient did not
need concomitant treatment with prednisone because
the RA disease activity was persistently low under
ABA treatment (DAS28 < 2.6).
Other authors reported a case of HBV reactivation
in an occult carrier receiving ABA as first biologic line
for RA [6]. In this case a treatment with tenofovir
300 mg/day was started and ABA was permanently
discontinued. A recent “real life” Italian study was car-
ried on 72 RA patients with concomitant HBV infec-
tion, treated with ABA plus steroids and conventional
Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Among them, 21 were occult carriers who received
prophylaxis with lamivudine only in 9 cases. No viral
reactivation was detected in a 24 months follow-up
period, underlining a safe profile of ABA during HBV
infection, also without applying antiviral prophylaxis
[7]. However, in our experience, a treatment with a
biologic agent inducing a peripheral tolerance could
favour the progression of HBV infection in an occult
carrier. The concomitant use of corticosteroids may
represent an aggravating factor, whereas the use of
methotrexate may be helpful in preventing the
immune-mediated damage to HBV-infected hepato-
cytes [8]. Therefore, HBV DNA and serum levels of
AST and ALT should be periodically monitored in oc-
cult carriers. In case of HBV reactivation patients can
be successfully treated with antiviral agents while
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continuing the treatment with ABA [9]. In conclusion,
reports remain still isolated in literature and, accord-
ing to our experience, this is the first case of HBV
reactivation under ABA in our cohort of RA patients
(n.9) affected by occult HBV infection.
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Fig. 1 Time-course of DAS28, AST, ALT and HBV DNA levels. DAS28: Disease Activity Score (28 Joints); AST: ASpartate aminotransferase; ALT:
ALanine aminotransferase; HBV DNA: Hepatitis B Virus DNA
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